Logo image of SRTA

STRATA CRITICAL MEDICAL INC (SRTA) Stock Fundamental Analysis

USA - NASDAQ:SRTA - US0926671043 - Common Stock

4.265 USD
-0.15 (-3.29%)
Last: 11/19/2025, 2:58:31 PM
Fundamental Rating

3

SRTA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 0 industry peers in the Unkown industry. While SRTA seems to be doing ok healthwise, there are quite some concerns on its profitability. SRTA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SRTA had negative earnings in the past year.
In the past year SRTA has reported a negative cash flow from operations.
SRTA had negative earnings in each of the past 5 years.
SRTA had a negative operating cash flow in each of the past 5 years.
SRTA Yearly Net Income VS EBIT VS OCF VS FCFSRTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M -50M

1.2 Ratios

Industry RankSector Rank
ROA 12.05%
ROE 14.27%
ROIC N/A
ROA(3y)-12.68%
ROA(5y)-33.09%
ROE(3y)-15.39%
ROE(5y)-48.99%
ROIC(3y)N/A
ROIC(5y)N/A
SRTA Yearly ROA, ROE, ROICSRTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

In the last couple of years the Gross Margin of SRTA has grown nicely.
Industry RankSector Rank
OM N/A
PM (TTM) 17.65%
GM 23.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.59%
GM growth 5YN/A
SRTA Yearly Profit, Operating, Gross MarginsSRTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for SRTA has been increased compared to 1 year ago.
Compared to 5 years ago, SRTA has more shares outstanding
SRTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SRTA Yearly Shares OutstandingSRTA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
SRTA Yearly Total Debt VS Total AssetsSRTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

SRTA has an Altman-Z score of 4.13. This indicates that SRTA is financially healthy and has little risk of bankruptcy at the moment.
There is no outstanding debt for SRTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.13
ROIC/WACCN/A
WACCN/A
SRTA Yearly LT Debt VS Equity VS FCFSRTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 4.39 indicates that SRTA has no problem at all paying its short term obligations.
SRTA has a Quick Ratio of 4.39. This indicates that SRTA is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 4.39
Quick Ratio 4.39
SRTA Yearly Current Assets VS Current LiabilitesSRTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

SRTA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.87%, which is quite impressive.
Looking at the last year, SRTA shows a decrease in Revenue. The Revenue has decreased by -5.40% in the last year.
Measured over the past years, SRTA shows a very strong growth in Revenue. The Revenue has been growing by 70.13% on average per year.
EPS 1Y (TTM)60.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
Revenue 1Y (TTM)-5.4%
Revenue growth 3Y70.13%
Revenue growth 5YN/A
Sales Q2Q%-34.16%

3.2 Future

SRTA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.23% yearly.
SRTA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.57% yearly.
EPS Next Y69.68%
EPS Next 2Y43.36%
EPS Next 3Y24.23%
EPS Next 5YN/A
Revenue Next Year-14.48%
Revenue Next 2Y4.69%
Revenue Next 3Y7.57%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SRTA Yearly Revenue VS EstimatesSRTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M
SRTA Yearly EPS VS EstimatesSRTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SRTA. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 209.07, SRTA can be considered very expensive at the moment.
SRTA is valuated expensively when we compare the Price/Forward Earnings ratio to 35.39, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 209.07
SRTA Price Earnings VS Forward Price EarningsSRTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150 200

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRTA Per share dataSRTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as SRTA's earnings are expected to grow with 24.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.36%
EPS Next 3Y24.23%

More info and screens

0

5. Dividend

5.1 Amount

SRTA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STRATA CRITICAL MEDICAL INC

NASDAQ:SRTA (11/19/2025, 2:58:31 PM)

4.265

-0.15 (-3.29%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)11-10 2025-11-10/bmo
Earnings (Next)03-11 2026-03-11/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change3.86%
Market Cap0
Revenue(TTM)228.76M
Net Income(TTM)40.39M
Analysts84.44
Price Target9.44 (121.34%)
Short Float %N/A
Short Ratio2.85
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-53.74%
Min EPS beat(2)-96.08%
Max EPS beat(2)-11.41%
EPS beat(4)1
Avg EPS beat(4)-16.86%
Min EPS beat(4)-96.08%
Max EPS beat(4)64.99%
EPS beat(8)3
Avg EPS beat(8)-46.19%
EPS beat(12)5
Avg EPS beat(12)-23.19%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)9.08%
Min Revenue beat(2)8.32%
Max Revenue beat(2)9.84%
Revenue beat(4)4
Avg Revenue beat(4)7.53%
Min Revenue beat(4)4.23%
Max Revenue beat(4)9.84%
Revenue beat(8)6
Avg Revenue beat(8)4.07%
Revenue beat(12)10
Avg Revenue beat(12)5.21%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)-350%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-28.22%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 209.07
P/S 1.44
P/FCF N/A
P/OCF N/A
P/B 1.17
P/tB 2.22
EV/EBITDA N/A
EPS(TTM)-0.27
EYN/A
EPS(NY)0.02
Fwd EY0.48%
FCF(TTM)-0.73
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS2.95
BVpS3.65
TBVpS1.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 12.05%
ROE 14.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 17.65%
GM 23.78%
FCFM N/A
ROA(3y)-12.68%
ROA(5y)-33.09%
ROE(3y)-15.39%
ROE(5y)-48.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.59%
GM growth 5YN/A
F-Score3
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 209.44%
Cap/Sales 6.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.39
Quick Ratio 4.39
Altman-Z 4.13
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)198.6%
Cap/Depr(5y)143.5%
Cap/Sales(3y)4.9%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
EPS Next Y69.68%
EPS Next 2Y43.36%
EPS Next 3Y24.23%
EPS Next 5YN/A
Revenue 1Y (TTM)-5.4%
Revenue growth 3Y70.13%
Revenue growth 5YN/A
Sales Q2Q%-34.16%
Revenue Next Year-14.48%
Revenue Next 2Y4.69%
Revenue Next 3Y7.57%
Revenue Next 5YN/A
EBIT growth 1Y56.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year132.15%
EBIT Next 3Y40.45%
EBIT Next 5YN/A
FCF growth 1Y-64.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.84%
OCF growth 3YN/A
OCF growth 5YN/A

STRATA CRITICAL MEDICAL INC / SRTA FAQ

What is the ChartMill fundamental rating of STRATA CRITICAL MEDICAL INC (SRTA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SRTA.


What is the valuation status for SRTA stock?

ChartMill assigns a valuation rating of 1 / 10 to STRATA CRITICAL MEDICAL INC (SRTA). This can be considered as Overvalued.


What is the profitability of SRTA stock?

STRATA CRITICAL MEDICAL INC (SRTA) has a profitability rating of 1 / 10.


How financially healthy is STRATA CRITICAL MEDICAL INC?

The financial health rating of STRATA CRITICAL MEDICAL INC (SRTA) is 6 / 10.